Vigabatrin
- Generic Name
- Vigabatrin
- Brand Names
- Sabril, Vigadrone, Kigabeq
- Drug Type
- Small Molecule
- Chemical Formula
- C6H11NO2
- CAS Number
- 68506-86-5
- Unique Ingredient Identifier
- GR120KRT6K
- Background
Vigabatrin is an analog of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although administered as a racemic mixture, only t...
- Indication
Vigabatrin is indicated as adjunctive therapy in the treatment of refractory complex partial seizures in patients 2 years of age and older who have had inadequate responses to multiple previous treatments (i.e. not to be used for first-line therapy). It is also indicated as monotherapy in the treatment of infantile spasms in patients between 1 month and 2 ye...
- Associated Conditions
- Infantile Spasms (IS), Refractory Complex partial seizures
- Associated Therapies
- -
A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Lundbeck LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01278173
- Locations
- 🇺🇸
CNMRI, Dover, Delaware, United States
🇺🇸Peachtree Neurological Clinic, Atlanta, Georgia, United States
🇺🇸OSF Saint Francis Medical Center, Peoria, Illinois, United States
Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 1
- Registration Number
- NCT01266291
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Vigabatrin Ph 1 Cocaine Interaction Study
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 24
- Registration Number
- NCT00626834
- Locations
- 🇺🇸
University of Texas Health Science Center, San Antonio, Texas, United States
Vigabatrin for Treatment of Cocaine Dependence
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT00611130
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center Center for Chemical Dependence, Baltimore, Maryland, United States
🇺🇸Addiction Treatment Clinic, Little Rock, Arkansas, United States
🇺🇸Friends Research Institute, Torrance, California, United States
Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
- Conditions
- Interventions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 100
- Registration Number
- NCT00527683
- Locations
- 🇲🇽
Clinica Integral de Tratamiento Contra las Adicciones SA de CV, Mexico City, Mexico, D.F., Mexico
Assessment of GVG for the Treatment of Methamphetamine Dependence
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT00506935
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Effects of Vigabatrin on Cocaine Self-Administration
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00373581
- Locations
- 🇺🇸
Irving Center for Clinical Research, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.